Early development form screens can be performed for a variety of reasons depending on the issues that are found during early development. We understand that different screens should be applied to different situations and we work with you to choose the best screen based on the issues that need to be resolved with your compound. For many compounds, low aqueous solubility can be a major challenge for oral dosage forms or other drug delivery routes. In these cases a salt, cocrystal or amorphous dispersion screen may be the best option. Other challenges can include hygroscopicity, chemical/physical stability, or melting point which may lead to a polymorph screen targeting a different crystalline form that may provide the solution. For early polymorph screens we use crystallization techniques that will favor the thermodynamically stable form to minimize form changes during storage and processing. Smaller abbreviated screens may be applicable at this stage to get initial information while there are still questions about the compound. We will provide options and risk assessments to help you understand the best way to move forward with selecting a form early in development.
bio-equip.cn
Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.
Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.
Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.
中文
